TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02322190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Description: Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Sterile solution used in conjunction with photopheresis procedure.
Study: NCT03628755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency Shaping Therapy
Description: FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluency Shaping Therapy
Description: FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combination Group
Description: combination group intervention of DMT + FST
Study: NCT03071978

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT with LV-only pacing / bi-ventricular pacing
Description: LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT with LV-only pacing / bi-ventricular pacing
Description: LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
Study: NCT01393340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01216579

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mannitol (an airway challenge agent)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mannitol (an airway challenge agent)
Study: NCT01897142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 1 micrograms per kilogram of PF-05230907, IV bolus, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 2 micrograms per kilogram of PF-05230907, IV bolus, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 3 micrograms per kilogram of PF-05230907, IV bolus, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 5 micrograms per kilogram of PF-05230907, IV bolus, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study: NCT02301273

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy
Description: o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Physiotherapy
Description: o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (\>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
Study: NCT03997149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Laboratory Stressor
Description: The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low affect video
Description: The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
Study: NCT01062282

Intervention type: DRUG
Intervention: Iloprost (Ventavis BAYQ6256)
Description: Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
Study: NCT03832582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Annexin
Description: All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
Study: NCT03441841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine + Prilocaine
Description: Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Single topical dose of 2g lidocaine 2.5 % formulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Single topical dose of 2g prilocaine 2.5 % formulation.
Study: NCT02418507

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proprietary Probiotic Blend
Description: A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is administered to randomized healthy participants
Study: NCT03326973

Intervention type: BEHAVIORAL
Intervention: EuroQoL EQ-5D-3L
Description: Overall QOL

Intervention type: BEHAVIORAL
Intervention: EORTC QLQ-C30
Description: General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales

Intervention type: OTHER
Intervention: PRO-CTCAE
Description: Additional potential immune-specific symptoms

Intervention type: BEHAVIORAL
Intervention: Fatigue severity score questionnaire
Description: Fatigue severity

Intervention type: BEHAVIORAL
Intervention: The COST
Description: Financial toxicity; satisfaction with ability to work

Intervention type: BEHAVIORAL
Intervention: Physician information
Description: Details on outside health providers
Study: NCT02464345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPIFED
Description: HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: CBT-E therapy
Study: NCT01589445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: 77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: 77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
Study: NCT03890549

Intervention type: DIAGNOSTIC_TEST
Intervention: SnoreLab (smart phone application for snoring recording)
Description: The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
Study: NCT03559179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Wizard
Description: The Opioid Wizard is an OUD clinical decision support tool for primary care providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Wizard
Description: The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
Study: NCT02562274

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MP 1500 mg/day
Description: Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
Study: NCT03051568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study: NCT01450397

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: XIAFLEX
Description: One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
Study: NCT00614614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)
Description: One dose in the booster phase as intramuscular injection
Study: NCT00043810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gelonin
Description: Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
Study: NCT00614614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)
Description: Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix®
Description: One dose as intramuscular injection
Study: NCT00283062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (TAXOTERE®) Chemotherapy
Description: 75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
Study: NCT00614614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix®
Description: One dose as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB®
Description: Three doses in the priming phase as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix®
Description: Three doses in the priming phase as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix®
Description: Three doses in the priming phase as intramuscular injection
Study: NCT00911404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low CHO
Description: Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High CHO diet
Description: Diet with 55% total calories from carbohydrates.
Study: NCT04549688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-intensity focused ultrasound, HIFU
Description: see above
Study: NCT03063658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
Study: NCT01097018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 BID/ Days 1-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 BID/ Days 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perifosine
Description: 50 mg daily x 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill daily x 21 days
Study: NCT00283062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
Study: NCT02063932

Intervention type: OTHER
Intervention: endomicroscopy, targeted biopsy and 16s rRNA gene sequencing
Study: NCT04101188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Potassium/Low Sodium Diet
Description: Consumption of 10 days of a diet moderate in potassium and low in sodium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Potassium/High Sodium Diet
Description: Consumption of 10 days of a diet moderate in potassium and high in sodium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Potassium/High Sodium Diet
Description: Consumption of 10 days of a diet high in potassium and high in sodium.
Study: NCT03731520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessing exercise behavior
Description: 11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
Study: NCT04361981

Intervention type: OTHER
Intervention: Deep Venous Disease Diagnostic
Description: Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
Study: NCT00668044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYO9867)
Description: 400 mg iv BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYO9867)
Description: 400 mg iv TID
Study: NCT00862810

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Received HPV vaccine first

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Received concomitant vaccines first
Study: NCT02246673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Study: NCT02937519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono-chemotherapy pump:Melodie

Intervention type: DEVICE
Group type: OTHER
Intervention: Routine intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction Chrono-chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: induction Routine-chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chrono-chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin routine-chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT01420523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir-Maraviroc
Description: Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
Study: NCT00690079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral admin. of doses at 11 days through a 12 days period.
Study: NCT04174430

Intervention type: BIOLOGICAL
Intervention: severe bronchiolitis
Description: Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
Study: NCT01466556

Intervention type: OTHER
Intervention: Routine laboratory tests
Description: Laboratory tests to determine metabolic syndrome
Study: NCT01745666

Intervention type: OTHER
Group type: OTHER
Intervention: exercise test
Description: Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
Study: NCT02937519

Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Study: NCT03888872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High tone power therapy
Description: 1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical Therapy Program
Description: Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical Therapy Program
Description: Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:
Study: NCT01745666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise test
Description: Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.